Updated results from the TALAPRO-2 trial “support talazoparib plus enzalutamide as a standard-of-care initial treatment option for patients with mCRPC,” according to Neeraj Agarwal, MD.

Researchers, including those from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, said in low ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

An indigenously developed gene therapy for specific blood cancers has shown a 73 per cent response rate among patients in ...

Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic ...

Advocates and clinicians say that patients are still having trouble getting refills, even though the FDA has lifted REMS for ...

Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

TOPLINE: Bispecific antibodies (BsAbs) demonstrated a manageable safety profile in patients with non-Hodgkin lymphoma (NHL), with 48% prevalence of all-grade cytokine release synd ...